Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cemiplimab

- PMLiVE

Keytruda adds another NSCLC approval in Europe

Squamous NSCLC completes first-line dominance

- PMLiVE

Gottlieb admonishes industry for clinical trial failings

Calls for faster uptake of novel trial design and methods

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

NCI head Sharpless named as interim FDA chief

The search for a permanent replacement is still ongoing

- PMLiVE

Tecentriq combo gains European NSCLC approval

Triple combination approved after targeted therapy

- PMLiVE

J&J’s Spravato breaks depression drought at FDA

The esketamine nasal spray is the first new-mechanism antidepressant to be licensed in decades

- PMLiVE

FDA chief Scott Gottlieb to step down

Won admiration of industry and public health experts

- PMLiVE

Trump’s Brexit trade plan is bad for NHS, say campaigners

People’s Vote claims US wants to end NHS’ current regime of controlling drug costs

- PMLiVE

Novartis back in the spotlight over Trump/Cohen links

Cohen said the fee intended to get him to work as a lobbyist

- PMLiVE

FDA and Flatiron extend real world evidence collaboration

Roche-owned specialists at forefront of big data analysis

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Intercept NASH drug closes in on FDA approval

Although the drug failed to meet secondary endpoint

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links